222 related articles for article (PubMed ID: 34742588)
1. Re: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med 2021;385:683-94: Adjuvant Pembrolizumab After Nephrectomy: A Plea to Reconsider the Need for Lymph Node Dissection.
Capitanio U; Larcher A; Montorsi F
Eur Urol; 2022 Jan; 81(1):e28. PubMed ID: 34742588
[No Abstract] [Full Text] [Related]
2. Re: Adjuvant Pembrolizumab After Nephrectomy in Renal-cell Carcinoma.
Grobet-Jeandin E; Pinar U; Rouprêt M
Eur Urol; 2022 Sep; 82(3):330. PubMed ID: 35551842
[No Abstract] [Full Text] [Related]
3. Re: Adjuvant Pembrolizumab After Nephrectomy in Renal-cell Carcinoma.
Magee DE; Kutikov A
Eur Urol; 2022 Mar; 81(3):317-318. PubMed ID: 34895924
[No Abstract] [Full Text] [Related]
4. [New drug approval: Adjuvant Pembrolizumab in clear-cell renal-cell carcinoma at high risk for recurrence after nephrectomy].
Brunet M; Malouf GG
Bull Cancer; 2022 Sep; 109(9):875-876. PubMed ID: 35778302
[No Abstract] [Full Text] [Related]
5. Re: Toni K. Choueiri, Thomas Powles, Laurence Albiges, et al. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. N Engl J Med 2023;388:1767-78.
Cerrato C; Pradere B; Mir MC
Eur Urol; 2023 Oct; 84(4):e93. PubMed ID: 37442718
[No Abstract] [Full Text] [Related]
6. Re: Pembrolizumab Versus Placebo as Post-nephrectomy Adjuvant Therapy for Clear Cell Renal Cell Carcinoma (KEYNOTE-564): 30-month Follow-up Analysis of a Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial.
Toribio-Vázquez C; Martinez-Piñeiro L
Eur Urol; 2024 Mar; 85(3):306. PubMed ID: 37957046
[No Abstract] [Full Text] [Related]
7. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. Reply.
Choueiri TK; Powles T
N Engl J Med; 2021 Nov; 385(20):1920. PubMed ID: 34758263
[No Abstract] [Full Text] [Related]
8. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Bleyer A
N Engl J Med; 2021 Nov; 385(20):1919-1920. PubMed ID: 34758262
[No Abstract] [Full Text] [Related]
9. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Sharma A; Sahoo RK; Batra A
N Engl J Med; 2021 Nov; 385(20):1919. PubMed ID: 34758261
[No Abstract] [Full Text] [Related]
10. Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy.
Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Rajwa P; Yanagisawa T; Mostafaei H; König F; Aydh A; Pradere B; Enikeev D; Karakiewicz PI; Schmidinger M; Shariat SF
Eur Urol Oncol; 2022 Feb; 5(1):120-124. PubMed ID: 34992006
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy with Autoimmune Complication in Renal Cancer.
Sunil SP; Kumar S; Hussaini S; Kandula S
J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116021
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK; Tomczak P; Park SH; Venugopal B; Ferguson T; Chang YH; Hajek J; Symeonides SN; Lee JL; Sarwar N; Thiery-Vuillemin A; Gross-Goupil M; Mahave M; Haas NB; Sawrycki P; Gurney H; Chevreau C; Melichar B; Kopyltsov E; Alva A; Burke JM; Doshi G; Topart D; Oudard S; Hammers H; Kitamura H; Bedke J; Perini RF; Zhang P; Imai K; Willemann-Rogerio J; Quinn DI; Powles T;
N Engl J Med; 2021 Aug; 385(8):683-694. PubMed ID: 34407342
[TBL] [Abstract][Full Text] [Related]
13. Cancer-specific mortality in patients with non-metastatic renal cell carcinoma who have undergone a nephrectomy and are eligible for adjuvant pembrolizumab.
Flammia RS; Hoeh B; Hohenhorst L; Sorce G; Chierigo F; Panunzio A; Tian Z; Saad F; Leonardo C; Briganti A; Antonelli A; Terrone C; Shariat SF; Graefen M; Chun FKH; Montorsi F; Gallucci M; Karakiewicz PI
Semin Oncol; 2022 Apr; 49(2):136-140. PubMed ID: 35610060
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab may be a new adjuvant treatment following renal cell carcinoma surgery.
Nierengarten MB
Cancer; 2021 Oct; 127(20):3713. PubMed ID: 34570910
[No Abstract] [Full Text] [Related]
15. Radical Nephrectomy with or without Lymph Node Dissection for High Risk Nonmetastatic Renal Cell Carcinoma: A Multi-Institutional Analysis.
Gershman B; Thompson RH; Boorjian SA; Larcher A; Capitanio U; Montorsi F; Carenzi C; Bertini R; Briganti A; Lohse CM; Cheville JC; Leibovich BC
J Urol; 2018 May; 199(5):1143-1148. PubMed ID: 29225056
[TBL] [Abstract][Full Text] [Related]
16. Lymphatic spread in renal cell carcinoma: have retroperitoneal lymph node dissection a therapeutic advantage?
Gilloz A; Lévigne F; Héritier P; Perraud Y; el Hajj E; Diez-Yanguas J
Prog Clin Biol Res; 1989; 303():729-30. PubMed ID: 2780669
[No Abstract] [Full Text] [Related]
17. Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis.
Gershman B; Thompson RH; Moreira DM; Boorjian SA; Lohse CM; Costello BA; Cheville JC; Leibovich BC
J Urol; 2017 Mar; 197(3 Pt 1):574-579. PubMed ID: 27663461
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab.
Serzan M; Atkins MB
Expert Rev Anticancer Ther; 2022 Jun; 22(6):565-574. PubMed ID: 35483033
[TBL] [Abstract][Full Text] [Related]
19. Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?
Massari F; Di Nunno V; Santoni M
Eur Urol Oncol; 2019 May; 2(3):340-341. PubMed ID: 31200852
[No Abstract] [Full Text] [Related]
20. Pembrolizumab: first adjuvant immunotherapy in renal cell carcinoma?
Saleh K; Kordahi M; Felefly T; Kourie HR; Khalife N
Future Oncol; 2022 Feb; 18(5):519-522. PubMed ID: 35067079
[No Abstract] [Full Text] [Related]
[Next] [New Search]
